GSK Announces US Approval of Hibsago for Selected Hepatitis B Patients

GSK announced that the FDA approved Hibsago for chronic hepatitis B in selected adult patients without cirrhosis who have received NrtI therapy for at least six months, have suppressed HBV DNA and have HBsAg levels at or below 3000 IU/ml as determined by an FDA-authorised test. The approval covers use in combination with NrtI therapy. GSK Press Releases report.

Approval scope and eligible population

The approval applies to adults with chronic hepatitis B virus infection who are not cirrhotic and who have taken NrtI therapy for at least six months. Patients must have suppressed HBV DNA and baseline HBsAg levels at or below 3000 IU/ml, measured by an FDA-authorised quantitative surface antigen test. Hibsago is approved with NrtI therapy.

GSK says several quantitative surface antigen tests are available, including a recently authorised FDA test, to identify patients within the labelled HBsAg threshold. The label ties treatment eligibility to a measured baseline characteristic and to prior NrtI exposure. The source does not state approval for patients outside these criteria.

Related coverage: related Biotech & Pharma reporting.

Trial evidence and functional cure

The approval was supported by pooled data from the B-Well phase III trials, which GSK describes as global, multicentre, randomised, double-blind and placebo-controlled studies in 29 countries. B-Well 1 and B-Well 2 each met the primary endpoint of functional cure in adults with baseline HBsAg at or below 3000 IU/ml, assessed after all therapies stopped.

GSK attributes higher functional cure rates to bepirovirsen plus NrtI therapy than to standard of care alone, and reports a key secondary result in participants with lower baseline HBsAg. Functional cure is defined as undetectable HBV DNA and HBsAg for at least 24 weeks after stopping all treatment, indicating immune control without medication. These are GSK-reported trial results, not independent benchmarks.

Related coverage: related Biotech & Pharma reporting.

Mechanism, dosing and administration

Bepirovirsen is an antisense oligonucleotide designed to recognise and inhibit production of viral RNA and proteins associated with hepatitis B. GSK says it reduces HBsAg in the blood and may stimulate the immune system to increase the chance of a durable response. GSK licensed the drug from Ionis and collaborated on development.

The approved course is six months, with the option of self-administration after the first dose. GSK presents that option as convenience. GSK continues regulatory submissions in multiple geographies, with decisions anticipated; bepirovirsen is approved in Japan and the US.

Related coverage: related Biotech & Pharma reporting.

Safety profile and stated limitations

GSK reports a safety and tolerability profile consistent with other bepirovirsen studies. The most frequently observed adverse events were injection site erythema, local pain and a temporary rise in a liver enzyme blood level. The source does not provide a full safety analysis or long-term post-marketing data.

The approved population excludes patients with cirrhosis and those without suppressed HBV DNA or baseline HBsAg above the labelled threshold. The source also does not establish clinical use beyond the combination with NrtI therapy. The label criteria are central to eligibility rather than broad hepatitis B coverage.

Related coverage: related Biotech & Pharma reporting.

What This Means for Practitioners

Inference: the commercial question is whether payers and clinicians will adopt a six-month regimen that requires baseline HBsAg testing and prior NrtI suppression. Conditional buyer question: if local testing capacity and reimbursement align with the label, would treatment pathways shift toward functional cure assessment? If not, would prescribing remain confined to centres already equipped for quantitative surface antigen testing?

Conditional research question: if longer follow-up confirms durable immune control after treatment stops, how should monitoring schedules be designed for the labelled population? If safety signals emerge outside trial settings, which subpopulations would require revised risk-benefit review? The source supports neither a cure claim for all CHB patients nor use beyond the approved criteria.